RO4929097
别名: RG-4733
目录号:S1575 Purity: 99.77%
RO4929097 (RG-4733)是一种γ secretase抑制剂,无细胞试验中IC50为4 nM,抑制Aβ40和Notch的细胞加工,EC50分别为14 nM和5 nM。Phase 2。
CAS: 847925-91-1
客户使用Selleck的RO4929097发表文献118篇
- Nature, 2022 603(7899):159-165
- Nature, 2020 10.1038/s41586-020-2946-9
- Science, 2020 eabb8598
- Cell Res, 2019 29(2):110-123
- Blood, 2019 134(19):1585-1597
- Mol Cancer, 2017 16(1):19
- Nat Cell Biol, 2016 18(1):7-20
- J Hematol Oncol, 2015 8:63
- J Hematol Oncol, 2015 8(1):9
- J Cell Physiol, 2024 10.1002/jcp.31291
- Cell Transplant, 2024 33:9636897241288932
- Res Sq, 2024 rs.3.rs-3843028
- Nat Commun, 2023 14(1):6190
- Cancers (Basel), 2023 15(6)1883
- Sci Rep, 2023 13(1):8659
- Clin Cancer Res, 2022 CCR-22-1128
- Clin Cancer Res, 2022 clincanres.2347.2021
- Cancer Lett, 2022 S0304-3835(22)00321-4
- Cell Death Dis, 2022 13(2):173
- Sci Rep, 2022 12(1):7
- Sci Rep, 2022 12(1):5221
- PLoS Genet, 2022 18(1):e1009968
- Invest Ophthalmol Vis Sci, 2022 63(10):14
- Cold Spring Harb Mol Case Stud, 2022 8(6)a006222
- SSRN, 2022
- Cell Death Differ, 2021 10.1038/s41418-021-00861-5
- Proc Natl Acad Sci U S A, 2021 118(22)e2026184118
- EBioMedicine, 2021 71:103575
- Cell Rep, 2021 37(1):109782
- Cell Rep, 2021 37(1):109774
- Oncogene, 2021 10.1038/s41388-020-01579-3
- Aging (Albany NY), 2021 13(9):12526-12536
- Biol Reprod, 2021 ioab056
- eNeuro, 2021 ENEURO.0468-20.2021
- Toxicol In Vitro, 2021 77:105233
- Hum Exp Toxicol, 2021 9603271211038743
- Adv Radiat Oncol, 2021 6(2):100622
- Nat Commun, 2020 11(1):5126
- Theranostics, 2020 10(6):2553-2570
- Theranostics, 2020 10(18):7956-7973
- Clin Cancer Res, 2020 10.1158/1078-0432.CCR-19-3420
- Mol Psychiatry, 2020 10.1038/s41380-020-0812-7
- Cell Rep, 2020 32(2):107883
- Cell Chem Biol, 2020 S2451-9456(20)30340-8
- Cells, 2020 9(1)
- Cells, 2020 9(6):E1484
- ACS Infect Dis, 2020 21
- Carcinogenesis, 2020 41(7):993-1004
- Sci Rep, 2020 10(1):1847
- Metabolites, 2020 10(8):E302
- J Cancer, 2020 11(19):5758-5767
- Pharm Res, 2020 37(10):185
- Dev Dyn, 2020 10.1002/dvdy.229
- Nat Commun, 2019 10(1):1530
- Cell Death Dis, 2019 10(10):763
- Elife, 2019 8
- Elife, 2019 10.7554/eLife.42930
- Sci Signal, 2019 12(567)
- Mol Cell Proteomics, 2019 18(9):1782-1795
- Ecotoxicol Environ Saf, 2019 178:159-167
- Thyroid, 2019 29(11):1683-1703
- Int J Cancer, 2019 10.1002/ijc.32293
- Mol Cancer Ther, 2019 18(7):1230-1242
- Front Pharmacol, 2019 10:1396
- J Cell Physiol, 2019 10.1002/jcp.29267
- Am J Cancer Res, 2019 9(8):1734-1745
- Sci Rep, 2019 9(1):5670
- Cell Mol Neurobiol, 2019 10.1007/s10571-019-00771-8
- Biochem Biophys Res Commun, 2019 510(3):376-382
- Evid Based Complement Alternat Med, 2019 2019:7912402
- J Vis Exp, 2019 (148)
- Theranostics, 2018 8(17):4795-4804
- Cell Death Differ, 2018 25(2):330-339
- Clin Cancer Res, 2018 24(10):2370-2382
- Cell Mol Life Sci, 2018 75(15):2813-2826
- Sci Rep, 2018 8(1):17987
- Cell Physiol Biochem, 2018 51(4):1518-1532
- J Cell Biochem, 2018 119(7):5913-5920
- Toxicol Sci, 2018 166(2):394-408
- Assay Drug Dev Technol, 2018 16(7):408-419
- Cell Rep, 2017 21(1):259-273
- Mol Cancer Ther, 2017 16(12):2759-2769
- Mol Cancer Res, 2017 15(12):1777-1791
- Sci Rep, 2017 7(1):14495
- Sci Rep, 2017 7:39751
- Development, 2017 144(8):1425-1440
- Biosci Rep, 2017 37(3)
- Stem Cells Dev, 2017 26(24):1735-1748
- Nature Communications, 2016 13616
- Nat Commun, 2016 7:11379
- Nat Commun, 2016 7:13616
- Cancer Lett, 2016 376(1):43-52
- Int J Mol Sci, 2016 17(4):531
- Oncotarget, 2016 7(44):71211-71222
- Oncotarget, 2016 7(51):84594-84607
- PLoS Genet, 2016 12(9):e1006279
- PLoS One, 2016 11(10):e0164660
- Cancer Biol Ther, 2016 17(9):966-75
- Nat Commun, 2015 6:7333
- Hepatology, 2015 10.1002/hep.28367
- Elife, 2015 10.7554/eLife.08261
- J Invest Dermatol, 2015 135(6):1521-1532
- Stem Cells Transl Med, 2015 4(11):1275-82
- Brain Tumor Pathol, 2015 32(3):176-83
- Dev Biol, 2015 10.1016/j.ydbio.2015.03.007
- Dev Cell, 2014 30(4):410-22
- PLoS One, 2014 9(3):e91983
- Dev Biol, 2014 394(1):83-93
- United states patent, 2014 Hans
- J Am Soc Nephrol, 2013 24(12):2023-33
- EMBO Mol Med, 2013 5(10):1502-22
- Breast Cancer Res, 2013 15(4):R54
- Oncotarget, 2013 4(10):1698-1711
- Stem Cells, 2013 32(1):301-12
- Carcinogenesis, 2013 34(7):1420-30
- Development, 2013 140(7):1402-11
- J Immunol, 2013 190(11):5516-25
- Biochem Biophys Res Commun, 2013 435(4):557-61
化学信息&溶解度
分子量 | 469.4 |
分子式 | C22H20F5N3O3 |
CAS号 | 847925-91-1 |
Smiles | CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3NC1=O |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 94 mg/mL ( 200.25 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 50 mg/mL Water : Insoluble DMSO : 93 mg/mL ( 198.12 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 93 mg/mL Water : Insoluble DMSO : 93 mg/mL ( 198.12 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 93 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:4.7mg/ml
(10.01mM)
操作示例:以 1 mL 工作液为例,取50μL94mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
95%saline
浓度:0.2mg/ml
(0.43mM)
操作示例:以1 mL工作液为例,取50 μL4mg/ml的澄清DMSO储备液加到950 μL生理盐水中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。